- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PGNX Market Currents
more »
-
May 8 Progenics Pharmaceuticals (PGNX): Q1 EPS of -$0.39 misses by $0.06. Revenue of $2.2M (-6.7% Y/Y). (PR)
Comment![Earnings, Healthcare]
PGNX in Focus
more »
PGNX Related Articles
more »
PGNX News
more »
-
at MarketWatch.com (Dec 20, 2011)
PGNX Press Releases and Filings
more »
-
GlobeNewswire (May 8, 2012)
-
Progenics Pharmaceuticals to Host Conference Call to Review First Quarter Financial Results on May 8GlobeNewswire (May 4, 2012)
-
GlobeNewswire (Mar 15, 2012)
-
GlobeNewswire (Mar 15, 2012)
-
GlobeNewswire (Mar 13, 2012)
PGNX Latest Transcript
more »
Currently, there are no transcripts for PGNX.
PGNX Cramer
more »
-
Thu, Apr 27, 2006
PGNX Instablog posts
more »
PGNX vs. ETF Alternatives
Company Description
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Our principal programs are directed toward... More
